Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
LeBlanc FR, Breese EH, Burns KC, Chang EK, Jones LM, Lee L, Mizukawa B, Norris RE, O'Brien MM, Phillips CL, Perentesis JP, Rubinstein J, Pommert L. LeBlanc FR, et al. Among authors: pommert l. Br J Haematol. 2024 Sep;205(3):1055-1066. doi: 10.1111/bjh.19679. Epub 2024 Jul 31. Br J Haematol. 2024. PMID: 39082439
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
Schafer ES, Rushing T, Crews KR, Annesley C, Colace SI, Kaiser N, Pommert L, Ramsey LB, Sabnis HS, Wong K, Chang BH, Cooper TM, Shah NN, Rheingold SR, Place AE, Chi YY, Bhojwani D, Wayne AS, Bernhardt MB. Schafer ES, et al. Among authors: pommert l. J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165. J Natl Cancer Inst. 2024. PMID: 38964343
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
Bender JD, Damodharan S, Capitini CM, Moskop A, Toner K, Vatsayan A, Talano JA, Baggott C, Schiff D, Katsanis E, Modi AJ, Quigg TC, Raikar SS, Schultz LM, Pommert L. Bender JD, et al. Among authors: pommert l. Blood Adv. 2024 Aug 13;8(15):4164-4168. doi: 10.1182/bloodadvances.2024012928. Blood Adv. 2024. PMID: 38916857 Free PMC article. No abstract available.
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.
Taylor ZL, Miller TP, Poweleit EA, DeGroote NP, Pommert L, Awoniyi O, Board SG, Ugboh N, Joshi V, Ambrosino N, Chavana A, Bernhardt MB, Schafer ES, O'Brien MM, Castellino SM, Ramsey LB. Taylor ZL, et al. Among authors: pommert l. Clin Transl Sci. 2023 Nov;16(11):2130-2143. doi: 10.1111/cts.13600. Epub 2023 Aug 3. Clin Transl Sci. 2023. PMID: 37503924 Free PMC article.
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
Gossai N, Bhojwani D, Schafer ES, Chang BH, Pommert L, Verma A, Malvar J, Chi YY, Hitzler J, Burke MJ, Rabin KR. Gossai N, et al. Among authors: pommert l. Leukemia. 2023 May;37(5):1138-1140. doi: 10.1038/s41375-023-01856-6. Epub 2023 Feb 22. Leukemia. 2023. PMID: 36813993 No abstract available.
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.
Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K. Kleman A, et al. Among authors: pommert l. Blood Adv. 2023 Sep 26;7(18):5549-5553. doi: 10.1182/bloodadvances.2022008953. Blood Adv. 2023. PMID: 36724511 Free PMC article. No abstract available.
27 results